These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 10663615

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT.
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V, Rigoli L, Lacquaniti A, Salpietro V, Piraino B, Amorini M, Salpietro C, Arrigo T.
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [Abstract] [Full Text] [Related]

  • 8. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 9. [Clinico-biological and immunohaematological profile of patients with β-thalassemia in Tunisia: about 26 cases].
    Romdhane H, Amara H, Abdelkefi S, Souyeh N, Chakroun T, Jarrey I, Bouslama M, Belhedi S, Houissa B, Boughammoura L, Jemni Yacoub S.
    Transfus Clin Biol; 2014 Dec; 21(6):309-13. PubMed ID: 25458984
    [Abstract] [Full Text] [Related]

  • 10. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2006 Dec; 30(2):219-27. PubMed ID: 16798647
    [Abstract] [Full Text] [Related]

  • 11. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
    Calleja EM, Shen JY, Lesser M, Grady RW, New MI, Giardina PJ.
    Ann N Y Acad Sci; 1998 Jun 30; 850():469-70. PubMed ID: 9668587
    [No Abstract] [Full Text] [Related]

  • 12. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Jun 30; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece.
    Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C.
    Ann N Y Acad Sci; 2005 Jun 30; 1054():445-50. PubMed ID: 16339695
    [Abstract] [Full Text] [Related]

  • 14. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P, Giua R, De Marco S, Bonetti MG, Amurri B, Masi C, Lazzari G, Rizzo C, Cervellera M, Peluso A.
    Haematologica; 1995 Jun 30; 80(5):398-404. PubMed ID: 8566878
    [Abstract] [Full Text] [Related]

  • 15. Treatment and complications of thalassemia major in Guangxi, Southern China.
    Yin XL, Wu ZK, He YY, Zhou TH, Zhou YL, Zhang XH.
    Pediatr Blood Cancer; 2011 Dec 15; 57(7):1174-8. PubMed ID: 21394896
    [Abstract] [Full Text] [Related]

  • 16. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
    Songdej D, Sirachainan N, Wongwerawattanakoon P, Sasanakul W, Kadegasem P, Sungkarat W, Chuansumrit A.
    Acta Haematol; 2015 Dec 15; 133(2):226-36. PubMed ID: 25376266
    [Abstract] [Full Text] [Related]

  • 17. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
    Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA.
    Ann Hepatol; 2013 Dec 15; 12(1):54-61. PubMed ID: 23293194
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P, Zarei T, Radwan AH, Taher AT, Karimi M.
    Transfus Med; 2015 Feb 15; 25(1):8-12. PubMed ID: 25801075
    [Abstract] [Full Text] [Related]

  • 19. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Feb 15; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 20. Pulmonary Functions in Children With Thalassemia Major.
    Ozyoruk D, Misirlioglu ED.
    J Pediatr Hematol Oncol; 2015 Nov 15; 37(8):605-10. PubMed ID: 26422288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.